Andere Sprachen IO Biotech, Inc.

Aktien

A3C6ZG

US4497781090

IOBT

Verzögert Nasdaq Andere Börsenplätze 18:21:33 25.04.2024			% 5 Tage	% 1. Jan.
1.44 ^USD	-1.37%		-2.04%	-23.40%

15.04.	IO Biotech gibt die Ernennung von Marjan Shamsaei zum Senior Vice President bekannt	CI
09.04.	IO Biotech, Inc. stellt auf der Aacr 2024 neue Daten vor, die den dualen Wirkmechanismus des führenden Krebsimpfstoffs Io102-Io103 weiter unterstützen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24.04.
IO Biotech : Corporate Deck April 2024	17.04.
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness	15.04.
IO Biotech Announces Marjan Shamsaei as Senior Vice President	15.04.
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103	09.04.
IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103	09.04.
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer	05.04.
IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer	05.04.
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting	06.03.
IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting	06.03.
IO Biotech : Corporate Deck March 2024	05.03.
IO Biotech, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05.03.
IO Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results	05.03.
IO Biotech to Present at 44th Annual Cowen Health Care Conference	26.02.
IO Biotech Doses First Patient in Phase 2 Trial of Melanoma Treatment	21.12.
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	21.12.
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial	21.12.
Basal Cell Carcinoma Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 (Updated)	20.12.
IO Biotech Announces 2023 Third Quarter Results	13.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen IO Biotech, Inc.

Aktien

A3C6ZG

US4497781090

IOBT

Andere Sprachen

Filter